01
Human Data and Indication Strategy
Use public human atlas and transcriptomic data to test mechanism, identify relevant cell populations, and compare and rank indications.
OpportunityEvidenceProtectionDevelopmentPositioning
Strategy for emerging life-sciences companies
Turn promising biology into a fundable, defensible development program.
Dalton Bohr integrates human-disease evidence, development strategy, patent architecture, regulatory planning, and partnering around the next value-creating decision.
Who we help
Built for emerging life-sciences companies at consequential inflection points.
Dalton Bohr works with discovery, preclinical, and clinical-stage organizations developing therapeutics, platforms, diagnostics, research tools, medical devices, and industrial biotechnology.
The best place to begin
The Strategy Blueprint
A focused engagement addressing one program and one consequential decision. Dalton Bohr integrates the available evidence, competitive environment, patent position, development requirements, and strategic options into a prioritized roadmap.
Starting at$7,500
What you receive
- ✓Written opportunity and risk assessment
- ✓Prioritized evidence and milestone roadmap
- ✓Patent, funding, regulatory, and partnering recommendations
- ✓Executive working session
Selected specialized capabilities
Specific work products for consequential milestones.
Engage these capabilities as focused projects, as part of a Strategy Blueprint, or through ongoing fractional support.
02Separate legal engagement
Patent and Portfolio Architecture
Draft and prosecute patent applications, architect claims and continuations, and align protection with the product and development strategy.
03
Rare Disease and Expedited Programs
Assess eligibility and prepare Orphan Drug, Rare Pediatric Disease, and Fast Track designation requests.
04
FDA Engagement Strategy
Frame the questions and prepare pre-IND, Type B, and Type C meeting requests, briefing packages, and response strategies.
05
Strategic Partnering and Relationships
Identify potential partners, position the opportunity, develop materials, and support outreach, introductions where appropriate, and diligence preparation.
Designation decisions and FDA feedback are determined by FDA. Patent and legal services require a separate written engagement and are subject to conflicts, jurisdiction, and professional-responsibility requirements.
Discuss a specialized engagement →Ways to engage
Choose the scope that matches the decision.
Start with a focused assessment or work product, then add ongoing leadership when the program requires it.
01
From $7,500
Strategy Blueprint
Assess one program and one consequential decision, then define the prioritized path forward.
- Integrated opportunity and risk assessment
- Decision-ready written roadmap
02
Scoped project
Specialized Work Product
Complete a defined atlas, designation, FDA, patent, funding, or partnering deliverable.
- Clear scope, inputs, and output
- Senior execution around one milestone
03
Ongoing support
Fractional Leadership
Add senior strategic or legal leadership without hiring a full-time executive.
- Strategy Lead: From $7,500 / month
- Patent and Legal Counsel: Custom monthly scope
Why Dalton Bohr
Senior judgment shaped inside biotechnology companies.
Dalton Bohr combines biotechnology legal and business-development leadership, registered patent practice, program-development strategy, and transaction experience.
Discuss a consequential decision
What decision or milestone is your program approaching?
Send a brief description of the technology, development stage, and decision in front of you. Dalton Bohr will confirm fit and recommend the most focused place to begin.
Request a 30-Minute Fit Discussion →